Want to see TSE:KNE full AI Analyst Report?
KNE Stock Chart & Stats
C$0.03
<C$0.01(20.00%)
At close: 4:00 PM EDT
C$0.03
<C$0.01(20.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.05
Previous CloseN/A
Volume17.00K
Average Volume (3M)38.18K
Market Cap
C$6.15M
Enterprise ValueC$7.26
Total Cash (Recent Filing)C$854.73K
Total Debt (Recent Filing)C$1.96M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding205,056,560
10 Day Avg. Volume23,974
30 Day Avg. Volume38,178
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.69
Price to Sales (P/S)15.17
P/FCF Ratio-1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Biofilm-disruption PlatformA focused biofilm-disruption platform addresses wound care and animal-health needs, giving Kane a defined technical niche. Applications across two healthcare-related markets can support reuse of know-how and broaden commercialization opportunities as products and partnerships develop over time.
Multiple Commercialization ChannelsThe company monetizes its technology through finished product sales, partner commercializations, supply arrangements, licensing or other contractual receipts, and collaboration work. This mix can diversify routes to market and extend reach beyond direct sales when partners adopt its technology.
Modest Debt And Cash-burn ImprovementDebt declined from approximately $2.3M in 2025 to about $2.0M TTM, while free-cash-flow burn improved versus 2025. These changes are modest and do not remove funding pressure, but they indicate some movement toward reducing obligations and containing cash use.
Bears Say
Sharp Revenue DeteriorationExtremely low and declining revenue indicates that current commercialization has not yet produced a sufficiently durable sales base. A 33.9% TTM decline reduces operating leverage, limits internally funded investment, and makes recovery dependent on materially stronger product or partner demand.
Severely Negative ProfitabilityGross and net margins at these levels show that the present cost structure is far above the revenue base, rather than merely reflecting modest operating pressure. Persistent losses can consume capital, constrain product development, and make sustainable profitability dependent on major revenue growth or cost restructuring.
Negative Equity And Ongoing Cash BurnNegative equity is a direct solvency warning, while substantial operating and free-cash-flow outflows show that losses are translating into real cash consumption. Together, these conditions reduce financial flexibility and increase the likelihood that continued operations require external funding.
KNE FAQ
What was Kane Biotech Inc’s price range in the past 12 months?
Kane Biotech Inc lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.
What is Kane Biotech Inc’s market cap?
Kane Biotech Inc’s market cap is C$6.15M.
When is Kane Biotech Inc’s upcoming earnings report date?
Kane Biotech Inc’s upcoming earnings report date is Nov 26, 2026 which is in 55 days.
How were Kane Biotech Inc’s earnings last quarter?
Kane Biotech Inc released its earnings results on Aug 27, 2026. The company reported -C$0.004 earnings per share for the quarter.
Is Kane Biotech Inc overvalued?
According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued.
Does Kane Biotech Inc pay dividends?
Kane Biotech Inc does not currently pay dividends.
What is Kane Biotech Inc’s EPS estimate?
Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech Inc have?
Kane Biotech Inc has 205,056,560 shares outstanding.
What happened to Kane Biotech Inc’s price movement after its last earnings report?
Kane Biotech Inc reported an EPS of -C$0.004 in its last earnings report. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Kane Biotech Inc?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kane Biotech Inc
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.